GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
ClinicalTrials.gov · NCT00707031 · Registry updated: 2016-12-02
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- Sanofi
- Countries with listed sites
- Argentina · Austria · Brazil · Colombia · Denmark · Finland · Germany · Greece · Hungary · Italy · Netherlands · Norway · Poland · Puerto Rico · Russia · Spain · Sweden · United States
- Registry dates and results
- Start: 2008-06. Completion: 2010-11 (may be estimated). Results are posted in this registry.
Products and interventions (5)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Lixisenatide (AVE0010) (drug)
- Pen auto-injector (device) — also listed as: OptiClik®
- Exenatide (drug) — also listed as: Byetta®
- Prefilled pen injector (device)
- Metformin (drug)
Where the study takes place — 18 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.